{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:49:38Z","timestamp":1765828178064},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Gastric cancer (GC) is the fifth most incident and the fourth deadliest cancer worldwide. GC is a heterogeneous disease from the histological and molecular standpoints. This malignancy is mostly diagnosed at advanced stages of the disease, where the available therapeutic interventions are not effective. The emergence of immunotherapy has transformed the landscape of cancer treatment, including GC, and currently immune checkpoint inhibitors have been approved for the treatment of patients with recurrent\/metastatic GC. This review summarizes the main clinical trials evaluating the use of immune checkpoint inhibitors in GC. It also highlights the potential of biomarkers for patient selection for GC immune checkpoint inhibition therapy, including programmed cell death ligand 1 expression and tumor mutational burden, and characteristics of the GC molecular classification, such as microsatellite instability status and Epstein-Barr virus infection, as predictors of response to blockade of the programmed cell death 1\/programmed cell death ligand 1 axis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/j.pbj.0000000000000162","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T17:24:39Z","timestamp":1644341079000},"page":"e162","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Recent insights into the use of immune checkpoint inhibitors in gastric cancer"],"prefix":"10.1097","volume":"7","author":[{"given":"Soraia","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Department of Pathology, Pathology and Oncology Unit, Faculty of Medicine of the University of Porto"}]},{"given":"Ceu","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pathology and Oncology Unit, Faculty of Medicine of the University of Porto"},{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Saude, Universidade do Porto (i3S)"},{"name":"Instituto de Patologia e Imunologia Molecular da Universidade do Porto (Ipatimup), Porto, Portugal."}]}],"member":"276","published-online":{"date-parts":[[2022,1]]},"reference":[{"key":"R1-20241001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"R3-20241001","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gutjnl-2018-318126","article-title":"British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma","volume":"68","author":"Banks","year":"2019","journal-title":"Gut."},{"key":"R4-20241001","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet."},{"key":"R5-20241001","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.3390\/ijms19092659","article-title":"What's new in gastric cancer: the therapeutic implications of molecular classifications and future perspectives","volume":"19","author":"Tirino","year":"2018","journal-title":"Int J Mol Sci."},{"key":"R6-20241001","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol."},{"key":"R7-20241001","first-page":"vi57","article-title":"Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Waddell","year":"2014","journal-title":"Eur J Surg Oncol."},{"key":"R8-20241001","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet."},{"key":"R9-20241001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAI.0b013e31821c821c","article-title":"HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment","volume":"20","author":"Kunz","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"R10-20241001","doi-asserted-by":"crossref","first-page":"e0182692","DOI":"10.1371\/journal.pone.0182692","article-title":"PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis","volume":"12","author":"Gu","year":"2017","journal-title":"PLoS One."},{"key":"R11-20241001","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.gtc.2013.01.004","article-title":"Pathology of gastric cancer and its precursor lesions","volume":"42","author":"Yakirevich","year":"2013","journal-title":"Gastroenterol Clin North Am."},{"key":"R12-20241001","first-page":"433","article-title":"Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions","volume":"5","author":"Karanikas","year":"2012","journal-title":"Onco Targets Ther."},{"key":"R13-20241001","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/1055-9965.EPI-13-1057","article-title":"Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention","volume":"23","author":"Karimi","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"R14-20241001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","article-title":"The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification","volume":"64","author":"Lauren","year":"1965","journal-title":"Acta Pathol Microbiol Scand."},{"key":"R15-20241001","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.annpat.2011.08.001","article-title":"WHO Classification of digestive tumors: the fourth edition [in French]","volume":"31","author":"Fl\u00e9jou","year":"2011","journal-title":"Ann Pathol."},{"key":"R16-20241001","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.gastro.2011.04.042","article-title":"Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy","volume":"141","author":"Tan","year":"2011","journal-title":"Gastroenterology."},{"key":"R17-20241001","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","article-title":"Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil","volume":"145","author":"Lei","year":"2013","journal-title":"Gastroenterology."},{"key":"R18-20241001","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ctrv.2019.05.005","article-title":"Comparison and applicability of molecular classifications for gastric cancer","volume":"77","author":"Serra","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"R19-20241001","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Cancer Genome Atlas Research NetworkComprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature."},{"key":"R20-20241001","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/ijms19061683","article-title":"Proposed Molecular and miRNA Classification of Gastric Cancer","volume":"19","author":"Alessandrini","year":"2018","journal-title":"Int J Mol Sci."},{"key":"R21-20241001","first-page":"277","article-title":"Pathogenesis of gastric cancer: genetics and molecular classification","volume":"400","author":"Figueiredo","year":"2017","journal-title":"Curr Top Microbiol Immunol."},{"key":"R22-20241001","doi-asserted-by":"crossref","first-page":"275","DOI":"10.14740\/gr1187","article-title":"Molecular classification of gastric adenocarcinoma","volume":"12","author":"Wang","year":"2019","journal-title":"Gastroenterology Res."},{"key":"R23-20241001","doi-asserted-by":"crossref","first-page":"44608","DOI":"10.18632\/oncotarget.10115","article-title":"Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget."},{"key":"R24-20241001","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"key":"R25-20241001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med."},{"key":"R26-20241001","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"key":"R27-20241001","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet."},{"key":"R28-20241001","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol."},{"key":"R29-20241001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet."},{"key":"R30-20241001","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol."},{"key":"R31-20241001","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J Clin Oncol."},{"issue":"(suppl_4)","key":"R32-20241001","first-page":"S1142","article-title":"LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer (GC\/GEJC)\/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study","volume":"31","author":"Moehler","year":"2020","journal-title":"Ann Oncol."},{"key":"R33-20241001","doi-asserted-by":"crossref","first-page":"S1192","DOI":"10.1016\/j.annonc.2020.08.2297","article-title":"LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric\/gastroesophageal junction (G\/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study","volume":"31","author":"Boku","year":"2020","journal-title":"Ann Oncol."},{"key":"R34-20241001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med."},{"key":"R35-20241001","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s10120-019-01034-7","article-title":"A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data","volume":"23","author":"Chen","year":"2020","journal-title":"Gastric Cancer."},{"key":"R36-20241001","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Cancer."},{"key":"R37-20241001","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/S0140-6736(17)32131-1","article-title":"Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?","volume":"390","author":"Chau","year":"2017","journal-title":"Lancet."},{"key":"R38-20241001","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10120-019-00970-8","article-title":"Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric\/gastroesophageal junction cancer","volume":"23","author":"Satoh","year":"2020","journal-title":"Gastric Cancer."},{"key":"R39-20241001","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1634\/theoncologist.2018-0221","article-title":"FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1","volume":"24","author":"Fashoyin-Aje","year":"2019","journal-title":"Oncologist."},{"key":"R42-20241001","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res."},{"key":"R43-20241001","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med."},{"key":"R44-20241001","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet."},{"key":"R45-20241001","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"R46-20241001","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet."},{"key":"R47-20241001","doi-asserted-by":"crossref","first-page":"37933","DOI":"10.1038\/srep37933","article-title":"The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep."},{"key":"R48-20241001","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10120-020-01090-4","article-title":"Current status of immune checkpoint inhibitors for gastric cancer","volume":"23","author":"Kono","year":"2020","journal-title":"Gastric Cancer."},{"key":"R49-20241001","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10120-016-0631-3","article-title":"Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients","volume":"20","author":"Kawazoe","year":"2017","journal-title":"Gastric Cancer."},{"key":"R50-20241001","doi-asserted-by":"crossref","first-page":"24269","DOI":"10.18632\/oncotarget.8169","article-title":"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients","volume":"7","author":"Boger","year":"2016","journal-title":"Oncotarget."},{"key":"R51-20241001","doi-asserted-by":"crossref","first-page":"80426","DOI":"10.18632\/oncotarget.12603","article-title":"Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group","volume":"7","author":"Chang","year":"2016","journal-title":"Oncotarget."},{"key":"R52-20241001","doi-asserted-by":"crossref","first-page":"112","DOI":"10.21037\/jgo-20-568","article-title":"Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis","volume":"12","author":"Qiu","year":"2021","journal-title":"J Gastrointest Oncol."},{"key":"R53-20241001","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J."},{"key":"R54-20241001","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-20-2980","article-title":"Efficacy of pembrolizumab monotherapy for advanced gastric\/gastroesophageal junction cancer with programmed death ligand 1 combined positive score >\/=10","volume":"27","author":"Wainberg","year":"2021","journal-title":"Clin Cancer Res."},{"key":"R55-20241001","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3892\/ijo.2015.3119","article-title":"Deficient mismatch repair: read all about it (review)","volume":"47","author":"Richman","year":"2015","journal-title":"Int J Oncol."},{"key":"R56-20241001","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s00018-018-2906-9","article-title":"Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches","volume":"75","author":"Ratti","year":"2018","journal-title":"Cell Mol Life Sci."},{"key":"R57-20241001","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archsurg.2009.42","article-title":"Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma","volume":"144","author":"Corso","year":"2009","journal-title":"Arch Surg."},{"key":"R58-20241001","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ijc.25495","article-title":"MSI phenotype and MMR alterations in familial and sporadic gastric cancer","volume":"128","author":"Leite","year":"2011","journal-title":"Int J Cancer."},{"key":"R59-20241001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/PAI.0000000000000264","article-title":"Clinicopathologic characteristics of microsatellite instable gastric carcinomas revisited: urgent need for standardization","volume":"25","author":"Mathiak","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol."},{"key":"R60-20241001","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bjs.10663","article-title":"Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer","volume":"105","author":"Polom","year":"2018","journal-title":"Br J Surg."},{"key":"R61-20241001","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13000-020-00979-z","article-title":"Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas","volume":"15","author":"Choi","year":"2020","journal-title":"Diagn Pathol."},{"key":"R62-20241001","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1097\/PAS.0000000000000698","article-title":"Programmeddeath-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability","volume":"40","author":"Ma","year":"2016","journal-title":"Am J Surg Pathol."},{"key":"R63-20241001","doi-asserted-by":"crossref","first-page":"100036","DOI":"10.1016\/j.esmoop.2020.100036","article-title":"Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials","volume":"6","author":"Pietrantonio","year":"2021","journal-title":"ESMO Open."},{"key":"R64-20241001","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1200\/JCO.20.00892","article-title":"Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100","volume":"39","author":"Moehler","year":"2021","journal-title":"J Clin Oncol."},{"key":"R65-20241001","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol."},{"key":"R66-20241001","first-page":"137e9","article-title":"Deregulation of immune response genesin patients with Epstein-Barr virus-associated gastric cancer and outcomes","volume":"148","author":"Kim","year":"2015","journal-title":"Gastroenterology."},{"key":"R67-20241001","doi-asserted-by":"crossref","first-page":"32925","DOI":"10.18632\/oncotarget.9076","article-title":"Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers","volume":"7","author":"Derks","year":"2016","journal-title":"Oncotarget."},{"key":"R68-20241001","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jnci\/djx213","article-title":"Immune activation and benefit from avelumab in EBV-positive gastric cancer","volume":"110","author":"Panda","year":"2018","journal-title":"J Natl Cancer Inst."},{"key":"R69-20241001","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med."},{"key":"R70-20241001","doi-asserted-by":"crossref","first-page":"e49020","DOI":"10.7554\/eLife.49020","article-title":"Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction","volume":"8","author":"Wang","year":"2019","journal-title":"Elife."},{"key":"R71-20241001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrc.2016.154","article-title":"Targeting neoantigens to augment antitumour immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"R72-20241001","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature."},{"key":"R73-20241001","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"R74-20241001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"R75-20241001","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med."},{"key":"R76-20241001","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med."},{"key":"R77-20241001","doi-asserted-by":"crossref","first-page":"e126908","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight."},{"key":"R78-20241001","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"R79-20241001","doi-asserted-by":"crossref","first-page":"e000374","DOI":"10.1136\/jitc-2019-000374","article-title":"Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer","volume":"8","author":"Lu","year":"2020","journal-title":"J Immunother Cancer."},{"key":"R80-20241001","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/annonc\/mdz197","article-title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432","volume":"30","author":"Wang","year":"2019","journal-title":"Ann Oncol."},{"key":"R81-20241001","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1200\/JCO.2020.38.15_suppl.4537","article-title":"The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061","volume":"38","author":"Shitara","year":"2020","journal-title":"J Clin Oncol."}],"container-title":["Porto Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T19:05:54Z","timestamp":1727809554000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/j.pbj.0000000000000162","relation":{},"ISSN":["2444-8664"],"issn-type":[{"type":"electronic","value":"2444-8664"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2021-04-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}